Am J Clin Nutr. 2026 Jun 25:101419. doi: 10.1016/j.ajcnut.2026.101419. Online ahead of print.

ABSTRACT

BACKGROUND: Icosapent ethyl (IPE), an ethyl ester of eicosapentaenoic acid (EPA, C20:5n-3), is thought to have immunomodulatory properties and may protect against colorectal cancer (CRC).

OBJECTIVES: This study aimed to assess the effect of IPE on changing total marine omega-3 polyunsaturated fatty acid (PUFA) and individual fatty acid composition in colorectal tissue.

METHODS: We conducted a prospective, single-arm clinical trial of 4g/d IPE (VASCEPA®) treatment for 8-12 weeks among patients with a recent history of adenoma. We collected pre- and post-treatment colorectal biopsies through flexible sigmoidoscopy, and participants’ diet and lifestyle via questionnaires. The primary outcome was the change in total marine omega-3 PUFA in colorectal tissue measured by gas-liquid chromatography. We examined changes in individual fatty acids exploratorily.

RESULTS: Among a total of 81 patients enrolled, 72 had paired pre- and post-treatment tissue fatty acid data. After intervention, the tissue composition (median [interquartile range]) of total marine omega-3 PUFA increased from 2.10% (0.96%) to 5.21% (1.97%), with a fold change of 2.40 (0.82). With a slight decrease in omega-6 PUFA (fold change = 0.96 [0.27]), the ratio of marine omega-3 to omega-6 PUFA increased (fold change = 2.58 [0.81]). Among individual fatty acids, EPA increased the most (fold change: 5.88 [3.63]). The cumulative amount of IPE treatment, rather than daily dosage, showed a positive correlation with changes in tissue EPA composition (Spearman’s ρ=0.23, P=0.051). The treatment effect on tissue EPA changes appeared to be stronger for participants with lower than higher dietary EPA intake at baseline, although the interaction tests did not reach statistical significance (P for interaction=0.26).

CONCLUSIONS: IPE treatment substantially increased incorporation of marine omega-3 PUFA, particularly EPA, into the colorectal tissue while reducing tissue omega-6 PUFA composition.

TRIAL REGISTRATION: The PREvention using EPA against coloREctal cancer (PREPARE) trial was registered as ClinicalTrials.gov identifier: NCT04216251.

PMID:42349681 | DOI:10.1016/j.ajcnut.2026.101419

The post Effect of icosapent ethyl treatment on colorectal tissue marine omega-3 polyunsaturated fatty acid levels among patients with a history of adenoma: a prospective, single-arm clinical trial appeared first on Fight Colorectal Cancer.

J Natl Cancer Inst. 2026 Jun 23:djag153. doi: 10.1093/jnci/djag153. Online ahead of print.

ABSTRACT

Increases in colorectal cancer (CRC) incidence among young adults were reported in 27 countries/territories worldwide, yet information on mortality trends is limited. Using the WHO Mortality database (1990 to 2023), we found CRC mortality rates among younger adults (25 to 49 years) increased in 18 of 49 countries (0.7-4.3%/year) during the most recent decade, decreased in 15, and were otherwise stable. Trends ranged from decreases of > 2%/year in Singapore, Belgium, and Denmark to increases of > 3%/year in Paraguay, Uruguay, Chile, and the UK. In half of the countries with increasing trends, rates in older adults (50 to 79 years) were stable (Colombia, Philippines, Croatia [women only]) or decreasing (Uruguay, the U.K., Australia, Canada, the U.S., Argentina). In the remainders-primarily in Latin America/the Caribbean-mortality rose in both groups. Increasing CRC mortality among younger adults may signal a growing future burden, reinforcing the need for etiologic investigation and heightened awareness to avert deaths through earlier detection.

PMID:42331356 | DOI:10.1093/jnci/djag153

The post Trends in colorectal cancer mortality among younger versus older adults in 49 countries appeared first on Fight Colorectal Cancer.

FOR IMMEDIATE RELEASE 

Climb for a Cure Goes Nationwide: Fight CRC Invites Supporters Across the Country to Join the July 18 Climb From Anywhere 

Virtual participation expands Fight CRC’s signature fundraising event, uniting climbers coast-to-coast in support of colorectal cancer research 

[CITY, STATE] — Fight Colorectal Cancer (Fight CRC) is launching a nationwide call to action: recruit 500 climbers in 30 days for its signature Climb for a Cure event on July 18. To reach that goal, Fight CRC is expanding participation beyond its in-person climbs in Arizona and New York, inviting supporters across the country to join as virtual climbers from anywhere. 

For nearly a decade, Climb for a Cure has brought together relentless champions committed to advancing colorectal cancer research and supporting families impacted by the disease. This year, participants can register for three options: a national climb July 17-19 in Flagstaff, AZ; a regional Climb Aug. 1 in Lake George, NY; or Climb Your Way, which allows participants to set their own challenge—whether that’s a mountain, a local trail, neighborhood stairs, or a treadmill workout. 

The goal is simple: 500 climbers. 30 days. One nationwide movement. 

“Climb for a Cure has always been about showing up, taking on challenges together, and proving that no one climbs alone,” said Katie McGinty, Donor Relations Manager at Fight CRC. “By expanding nationwide, we’re creating an opportunity for people everywhere to be part of something bigger than themselves. Whether you’re climbing a mountain, walking your neighborhood, or simply taking the stairs at work, every step helps fuel research and bring hope to families facing colorectal cancer.” 

Participation in Climb Your Way is free, and no travel is required. Fight CRC is encouraging supporters to register at fightcrc.org/climb as virtual climbers and set a fundraising goal of at least $250. Every step taken supports groundbreaking genetics research, amplifies survivor stories, and advances Fight CRC’s Path to a Cure. 

Since its launch in 2016, Climb for a Cure has raised more than $1 million for research and programs that directly impact the colorectal cancer community. Funds raised have supported initiatives including Fight CRC’s research grants, Early-Onset Colorectal Cancer Think Tanks, and other efforts designed to accelerate progress toward a cure. 

Fight CRC is calling on supporters from every state to join the movement and help demonstrate the power of a united community. 

Join Climb for a Cure from anywhere and register today at fightcrc.org/climb. 

About Fight Colorectal Cancer 

Fight Colorectal Cancer (Fight CRC) is the leading patient-empowerment and advocacy organization dedicated to curing colorectal cancer and serving the needs of patients and families. Fight CRC advocates for research, provides educational resources, and empowers a community of champions working toward a world without colorectal cancer. 

The post 2026 Virtual Climb Press Release appeared first on Fight Colorectal Cancer.

When new research is presented at a major conference like the American Society of Clinical Oncology (ASCO) Annual Meeting, the headlines often focus on breakthrough treatments, clinical trial results, and emerging technologies. But for people living with colorectal cancer, the questions are often more personal. 

Will this improve treatment options? Will it help prevent recurrence? Will insurance cover it? And what about the side effects and challenges that continue long after treatment ends? 

Ahead of ASCO 2026, Fight CRC invited members of our community to share the topics they hoped researchers would address. While not every question received a definitive answer, the meeting offered important insights into several areas patients continue to prioritize. 

Precision Medicine Continues to Advance 

One of the clearest themes from ASCO 2026 was the continued evolution of precision medicine. Researchers presented new data exploring how biomarkers can help guide treatment decisions and identify which therapies are most likely to benefit individual patients. 

Circulating tumor DNA (ctDNA) remained a major area of focus. Ongoing studies continue to evaluate how ctDNA can help identify recurrence risk after surgery and potentially guide treatment decisions. While questions remain about insurance coverage and implementation, the field continues to move toward more personalized approaches to care. 

For patients, the takeaway is clear: comprehensive biomarker testing is becoming increasingly important throughout the colorectal cancer journey. 

New Opportunities for KRAS- and BRAF-Driven Cancers 

Research focused on KRAS and BRAF mutations continues to gain momentum. 

Updated findings from the BREAKWATER study reinforced the growing role of targeted therapies for patients with BRAF V600E metastatic colorectal cancer. Researchers are also exploring next-generation approaches aimed at improving outcomes and overcoming treatment resistance. 

Meanwhile, the pipeline for KRAS-targeted therapies continues to expand. Once considered “undruggable,” KRAS has become one of the most active areas in colorectal cancer research, with multiple therapies and combination strategies currently under investigation. 

While many of these approaches remain in clinical trials, they represent meaningful progress for patients whose tumors carry these mutations. 

Researchers Continue Searching for Answers in MSS Disease 

Many patients continue to ask about immunotherapy for microsatellite stable (MSS) colorectal cancer, which represents the majority of colorectal cancer cases. 

Although ASCO 2026 did not deliver a new immunotherapy standard for MSS disease, researchers presented several studies exploring ways to make immunotherapy more effective through combination approaches and novel treatment strategies. 

Progress may be slower than patients and clinicians would like, but MSS colorectal cancer remains a major focus of ongoing research. 

Survivorship Is Part of the Research Conversation 

Patients consistently tell us that surviving cancer is only part of the story. Living well after treatment matters, too. 

Throughout ASCO, discussions increasingly reflected the need for more research focused on neuropathy, bowel dysfunction, fatigue, and other long-term effects of treatment. While survivorship research still receives less attention than drug development, there is growing recognition that quality of life should be considered alongside traditional measures like response rates and survival. 

As more people live longer with and beyond colorectal cancer, understanding the long-term impact of treatment will become increasingly important.  

Progress Requires Access 

Many of the advances discussed at ASCO depend on a patient’s ability to access testing, treatment, and clinical trials. 

Whether discussing ctDNA, precision medicine, Lynch syndrome surveillance, or emerging therapies, access remains a critical issue. Scientific innovation only benefits patients when it is available, affordable, and supported by healthcare systems and insurance coverage. 

That is why advocacy remains essential—not only to advance research, but also to ensure patients can benefit from the progress being made. 

Looking Ahead 

ASCO 2026 reinforced several encouraging trends in colorectal cancer research. Precision medicine continues to expand, targeted therapies are creating new opportunities for patients with specific biomarkers, researchers remain committed to improving outcomes for MSS disease, and survivorship is receiving greater attention. 

While many questions remain, one thing is clear: the priorities of the colorectal cancer community continue to shape the future of research. 

At Fight CRC, we remain committed to elevating patient voices and translating emerging science into meaningful information for the community we serve. 

The post Beyond the Headlines: What the Colorectal Cancer Community Wanted to Know After ASCO 2026 appeared first on Fight Colorectal Cancer.

Clinical Trials Roundup

Curated by Fight CRC’s Medical Advisory Board & Research Advocacy Training and Support (RATS) team.

This month, we’re spotlighting actively recruiting colorectal cancer clinical trials connected to themes from the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, including biomarker-driven care, ctDNA research, immunotherapy combinations, antibody-drug conjugates, and targeted therapies.

Clinical trials help researchers learn what may work, for whom, and when. These summaries can help patients and caregivers start informed conversations with their care team. 

Need help understanding clinical trials or biomarker testing? See our resources.

June 2026

1. HARMONi-GI3 — Ivonescimab + mFOLFOX6 in First-Line Metastatic Colorectal Cancer

Biomarker Focus: Metastatic colorectal cancer; immunotherapy and VEGF pathway strategy
Phase / Sites: Phase III / Multicenter
Stage: Metastatic colorectal cancer
Recruitment Status: Recruiting
What It’s Studying:
This study compares ivonescimab plus mFOLFOX6 chemotherapy with bevacizumab plus mFOLFOX6 for patients who have not yet received systemic treatment for metastatic CRC.
Why It Matters:
First treatment decisions can feel urgent and overwhelming. This trial is studying whether combining chemotherapy with a treatment that targets both immune response and tumor blood-vessel growth may offer another first-line approach.
Patient Tip:
Ask your care team: “Do I know my MSI/MMR status, and are there any first-line clinical trials that match my diagnosis and treatment goals?”
ClinicalTrials.gov: NCT07228832

2. BAY 3771249 — KRAS G12D-Targeted Therapy for Advanced or Metastatic CRC

Biomarker Focus: KRAS G12D mutation
Phase / Sites: Phase I / Multicenter
Stage: Advanced or metastatic colorectal cancer
Recruitment Status: Recruiting
What It’s Studying:
This study is evaluating BAY 3771249, an investigational treatment being studied alone or with cetuximab for patients with advanced or metastatic CRC that has a KRAS G12D mutation.
Why It Matters:
KRAS G12D has limited targeted treatment options. This trial reflects the growing effort to develop therapies based on the exact KRAS mutation driving a person’s cancer.
Patient Tip:
Ask your care team: “Do I have a KRAS G12D mutation, and are there trials designed specifically for this subtype?”
ClinicalTrials.gov: NCT07535112

3. SGN-CEACAM5C — Antibody-Drug Conjugate Targeting CEACAM5

Biomarker Focus: CEACAM5 expression
Phase / Sites: Phase I / International study with U.S. sites
Stage: Advanced solid tumors, including colorectal cancer cohorts
Recruitment Status: Recruiting
What It’s Studying:
This study is evaluating SGN-CEACAM5C, also known as PF-08046050, in adults with advanced solid tumors, including CRC cohorts. Antibody-drug conjugates are designed to deliver treatment more directly to cancer cells with a specific target.
Why It Matters:
When standard treatments stop working, patients often want to know what other options are being studied. This trial is one example of research exploring more targeted approaches for advanced CRC.
Patient Tip:
Ask your care team: “Has my tumor been tested for markers that could help match me to a targeted therapy or antibody-drug conjugate trial?”
ClinicalTrials.gov: NCT06131840

4. EMPIRE / NSABP FC-13 — Immunotherapy for ctDNA-Positive Minimal Residual Disease

Biomarker Focus: ctDNA-positive minimal residual disease after colorectal cancer treatment
Phase / Sites: Phase II / Multicenter
Stage: Colorectal cancer after definitive surgery and chemotherapy, with ctDNA positivity
Recruitment Status: Recruiting
What It’s Studying:
EMPIRE is studying cemiplimab alone or with other immunotherapy-based treatments for people with CRC who are ctDNA-positive after surgery and chemotherapy. ctDNA is tumor DNA that can sometimes be detected through a blood test.
Why It Matters:
Many patients want to know what ctDNA results may mean for recurrence risk and next steps. This study is asking whether immunotherapy-based treatment can help delay or prevent colorectal cancer from coming back in patients with ctDNA-positive minimal residual disease.
Patient Tip:
If you have completed surgery and chemotherapy, ask your care team: “Is ctDNA testing appropriate for me, and would a positive result change my follow-up plan or clinical trial options?”
ClinicalTrials.gov: NCT07058012

5. KANDLELIT-012 — Calderasib (MK-1084) + Cetuximab + mFOLFOX6 for KRAS G12C-Mutated Colorectal Cancer

Biomarker Focus: KRAS G12C mutation
Phase / Sites: Phase III / Multicenter
Stage: Locally advanced unresectable or metastatic colorectal cancer
Recruitment Status: Recruiting
What It’s Studying:
This study is evaluating calderasib, also known as MK-1084, with cetuximab and mFOLFOX6 chemotherapy compared with mFOLFOX6 with or without bevacizumab in KRAS G12C-mutated CRC.
Why It Matters:
KRAS mutations are common in CRC, but not all KRAS mutations are the same. This trial focuses on KRAS G12C and reflects the movement toward treatments matched to specific tumor biomarkers.
Patient Tip:
If your care team says your tumor has a KRAS mutation, ask: “Which KRAS mutation do I have, and does that specific result make me eligible for any clinical trials?”
ClinicalTrials.gov: NCT06997497

6. Bonus Research Watch: CRDF-004 — Onvansertib + Chemotherapy and Bevacizumab for RAS-Mutated Metastatic Colorectal Cancer

Biomarker Focus: KRAS or NRAS mutation
Phase / Sites: Phase II / U.S. multicenter study
Stage: First-line metastatic colorectal cancer
Recruitment Status: Active, not recruiting
What It’s Studying:
CRDF-004 is studying onvansertib with standard chemotherapy and bevacizumab for adults with metastatic CRC that has a KRAS or NRAS mutation.
Why It Matters:
RAS mutations are common in metastatic CRC, and researchers continue to look for better first-line strategies. This trial is not currently recruiting, but it remains important to watch because ASCO 2026 featured interim results from CRDF-004 in first-line RAS-mutated metastatic CRC.
Patient Tip:
If your tumor has a KRAS or NRAS mutation, ask your care team: “Are there current or upcoming trials for RAS-mutated colorectal cancer that may fit my treatment plan?”
ClinicalTrials.gov: NCT06106308

May 2026

1. NCI ComboMATCH — Combination Therapy Based on Tumor Genetics 

Biomarker Focus: Actionable genetic alterations 
Phase / Sites: Screening trial supporting multiple Phase II treatment sub-studies  / U.S. NCI network 
Stage: Advanced solid tumors, including colorectal cancer when biomarker eligible 
Recruitment Status: Recruiting 
What it’s studying: ComboMATCH assigns patients to treatment combinations based on tumor genetic changes rather than cancer type alone, using a screening platform that matches patients to specific sub-studies. 
Why it matters: This builds on precision medicine by testing whether targeted drug combinations can improve outcomes for patients whose tumors have actionable alterations. 
Patient Tip: If you’ve had genomic testing, ask whether your results include an alteration that could match to a precision medicine trial. 
ClinicalTrials.gov: NCT05564377 
https://clinicaltrials.gov/study/NCT05564377 

2. BASECAMP-1 — Screening Study for Future CEA-Targeted Cell Therapy 

Biomarker Focus: CEA expression, HLA type (including HLA loss of heterozygosity), tumor immune markers 
Phase / Sites: Observational screening study / U.S. sites 
Stage: Solid tumors, including colorectal cancer 
Recruitment Status: Recruiting 
What it’s studying: BASECAMP-1 screens patients for biomarkers that may determine eligibility for future CEA-targeted cell therapy studies. 
Why it matters: This expands biomarker testing beyond tumor mutations to include immune matching and cell therapy eligibility. 
Patient Tip: If you’re interested in cell therapy trials, ask whether HLA typing or CEA testing could be relevant. 
ClinicalTrials.gov: NCT04981119 
https://clinicaltrials.gov/study/NCT04981119 

3. Onvansertib Combination Trial — KRAS-Mutant Metastatic Colorectal Cancer 

Biomarker Focus: KRAS mutation 
Phase / Sites: Phase II / U.S. and international sites 
Stage: Metastatic colorectal cancer 
Recruitment Status: Active, Not Recruiting 
What it’s studying: This study evaluates onvansertib with standard chemotherapy and bevacizumab in patients with KRAS-mutant metastatic colorectal cancer. 
Why it matters: KRAS mutations are common in CRC, but many KRAS-mutant tumors still lack effective targeted options. This study focuses on a biologically defined CRC group. 
Patient Tip: If your tumor has a KRAS mutation, ask whether the specific KRAS variant and prior treatments affect trial eligibility. 
ClinicalTrials.gov: NCT06106308 
https://clinicaltrials.gov/study/NCT06106308 

4. P-MUC1C-ALLO1 — Allogeneic CAR-T Cell Therapy Targeting MUC1-C 

Biomarker Focus: MUC1-C expression 
Phase / Sites: Phase I / Includes U.S. sites 
Stage: Advanced or metastatic solid tumors, including colorectal cancer 
Recruitment Status: Active, Not Recruiting 
What it’s studying: This study evaluates an allogeneic CAR-T cell therapy targeting MUC1-C, a tumor-associated marker expressed in several epithelial cancers. 
Why it matters: Cell therapy research in CRC is expanding, and biomarker testing may help identify patients whose tumors express targets like MUC1-C. 
Patient Tip: Ask whether your tumor testing includes protein-expression markers, not just DNA mutations. 
ClinicalTrials.gov: NCT05239143 
https://clinicaltrials.gov/study/NCT05239143 

5. GCC19CART — CAR-T Therapy Targeting GCC in Advanced Gastrointestinal Cancers 

Biomarker Focus: GCC / guanylyl cyclase C expression 
Phase / Sites: Phase I / U.S. sites 
Stage: Metastatic colorectal cancer 
Recruitment Status: Recruiting 
What it’s studying: This trial evaluates CAR-T cells targeting GCC, a marker commonly associated with colorectal cancer cells. 
Why it matters: GCC-targeted cell therapy is a CRC-relevant biomarker strategy and represents a newer research direction for patients with advanced disease. 
Patient Tip: If you are exploring cell therapy options, ask whether your tumor expresses GCC or whether a GCC-targeted study is available. 
ClinicalTrials.gov: NCT05319314 
https://clinicaltrials.gov/study/NCT05319314 

April 2026

1. JANUS Rectal Cancer Trial — Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer 
Biomarker Focus: Response-adapted treatment and organ preservation strategy 
Phase / Sites: Phase II / U.S. cooperative group, multicenter 
Stage: Stage II-III / locally advanced rectal cancer 
Recruitment Status: Active, not recruiting 
What it’s studying: JANUS is comparing long-course chemoradiation followed by mFOLFIRINOX versus mFOLFOX6 to improve clinical complete response and organ preservation in locally advanced rectal cancer. 
Why it matters: This study is relevant right now because it focuses on treatment intensification and organ-preservation goals in rectal cancer—an area of strong interest for patients and clinicians alike. 
Patient Tip: If you are discussing treatment before rectal cancer surgery, ask whether total neoadjuvant therapy or organ-preservation strategies may be appropriate for you. 
ClinicalTrials.gov: NCT05610163 
https://clinicaltrials.gov/study/NCT05610163 

2. EA2201 — Immunotherapy in dMMR Stage II/III Rectal Cancer 
Biomarker Focus: Deficient mismatch repair (dMMR) / MSI-H 
Phase / Sites: Phase II / Multicenter U.S. trial 
Stage: Stage II–III locally advanced rectal adenocarcinoma 
Recruitment Status: Active, not recruiting 
What it’s studying: EA2201 is evaluating nivolumab + ipilimumab with short-course radiation in patients with MSI-H/dMMR rectal cancer, with the goal of improving response while potentially reducing the need for more intensive conventional treatment. 
Why it matters: dMMR rectal cancer is one of the clearest examples of biomarker-driven care in CRC. This trial reflects the shift toward tailoring treatment based on tumor biology. 
Patient Tip: If your tumor is dMMR or MSI-H, ask whether immunotherapy-based trials may be available before surgery. 
ClinicalTrials.gov: NCT04751370 
https://clinicaltrials.gov/study/NCT04751370 

3. COMMIT Study — First-Line Immunotherapy Strategy in Metastatic dMMR/MSI-H Colorectal Cancer 
Biomarker Focus: dMMR / MSI-H 
Phase / Sites: Phase III / national multicenter trial 
Stage: Metastatic colorectal cancer 
Recruitment Status: Active, not recruiting 
What it’s studying: COMMIT is testing atezolizumab-based first-line treatment strategies, including chemotherapy/bevacizumab-containing approaches, in metastatic dMMR CRC. 
Why it matters: Although immunotherapy is already important in dMMR/MSI-H CRC, not all patients have durable benefit. COMMIT is trying to refine the best first-line approach for this population. 
Patient Tip: If you have metastatic dMMR/MSI-H CRC and are starting treatment, ask whether a first-line immunotherapy trial is an option. 
ClinicalTrials.gov: NCT02997228 
https://clinicaltrials.gov/study/NCT02997228 

4. ERAS-007 Combination Trial in Advanced Gastrointestinal Malignancies, Including Colorectal Cancer 
Biomarker Focus: MAPK pathway / BRAF and RAS pathway signaling 
Phase / Sites: Phase Ib/II / Multicenter, including U.S. sites 
Stage: Advanced gastrointestinal malignancies, including metastatic CRC 
Recruitment Status: Completed 
What it’s studying: This study is evaluating ERAS-007, an ERK inhibitor, in combination regimens designed to interrupt downstream MAPK signaling in GI cancers, including CRC. 
Why it matters: Many CRC tumors are driven by pathway alterations that remain difficult to target directly. ERAS-007 reflects a newer strategy aimed at blocking downstream signaling to improve outcomes. 
Patient Tip: If your cancer has a BRAF or RAS-pathway alteration, ask whether downstream pathway-targeting trials may be appropriate. 
ClinicalTrials.gov: NCT05039177 
https://clinicaltrials.gov/study/NCT05039177 

5. Nous-209 Vaccine Prevention Study in Lynch Syndrome 
Biomarker Focus: Lynch syndrome / mismatch repair deficiency risk 
Phase / Sites: Phase Ib/II / U.S.-based prevention study 
Stage: High-risk individuals with Lynch syndrome 
Recruitment Status: Active, not recruiting 
What it’s studying: This study is evaluating the Nous-209 vaccine strategy for cancer prevention in Lynch syndrome carriers at elevated risk for colon and other Lynch-associated cancers. 
Why it matters: This is a prevention-focused trial rather than a treatment trial, but it is highly relevant to colorectal cancer because it aims to reduce future cancer risk in a well-defined high-risk population. 
Patient Tip: If you or your family members have Lynch syndrome, ask whether prevention studies or surveillance-focused research may be appropriate. 
ClinicalTrials.gov: NCT05078866 

https://clinicaltrials.gov/study/NCT05078866

March 2026

1. ARPA-H ADAPT Oncology Platform – Colorectal Cohort 

Biomarker Focus: Real-time biomarker integration and adaptive trial infrastructure 
Phase / Sites: Early research initiative / United States 
Stage: Colorectal cancer (see eligibility criteria in protocol) 
Recruitment Status: Not yet recruiting 
What it’s studying: This ARPA-H supported initiative is part of the ADAPT oncology platform, designed to modernize how cancer clinical trials are conducted. The platform integrates advanced biomarker monitoring, coordinated data systems, and adaptive treatment strategies to accelerate therapeutic development in CRC and other cancers. 
Why it matters: Rather than testing a single drug, this national investment focuses on transforming the clinical trial system itself — potentially speeding up how promising treatments move from concept to clinic. 
Patient Tip: Even if enrollment hasn’t begun, ask your care team about upcoming federally funded research programs that may open new opportunities. 
ClinicalTrials.gov: NCT07318389

2. Molecularly Guided Therapy Based on Tumor Genetics: NCI-MATCH 

Biomarker Focus: Actionable genetic mutations 
Phase / Sites: Phase 2 / Nationwide (NCI-sponsored) 
Stage: Advanced solid tumors, including colorectal cancer 
Recruitment Status: Active, not recruiting 
What it’s studying: NCI-MATCH assigns treatment based on specific genetic mutations found in a tumor rather than the cancer’s location in the body. Patients with colorectal cancer whose tumors harbor actionable mutations may be matched to targeted therapies designed for those alterations. 
Why it matters: This national precision-medicine trial helped redefine how we think about treatment selection. Instead of a one-size-fits-all approach, MATCH reflects a shift toward therapy guided by tumor biology. 
Patient Tip: If you’ve had comprehensive genomic testing, ask whether your tumor’s mutations may qualify you for a MATCH sub-study. 
ClinicalTrials.gov: NCT02465060

3. COBRA Trial: ctDNA-Guided Predictor in Stage IIA 

Biomarker Focus: Circulating tumor DNA (ctDNA) 
Phase / Sites: Phase 2/3 / U.S. cooperative groups 
Stage: Stage II colon cancer 
Recruitment Status: Active 
What it’s studying: The COBRA study evaluates whether ctDNA testing after surgery can identify patients who truly need chemotherapy and who may safely avoid it. 
Why it matters: This study reflects the growing role of blood-based biomarkers in guiding adjuvant therapy, with the goal of reducing overtreatment while maintaining excellent outcomes. 
Patient Tip: If you have stage II colon cancer, ask whether ctDNA testing is appropriate for you and whether participation in a biomarker-guided trial is an option. 
ClinicalTrials.gov: NCT04068103

4. SWOG S2107: Immunotherapy Strategies in MSS Metastatic CRC 

Biomarker Focus: Microsatellite stable (MSS) and BRAF V600E mutation 
Phase / Sites: Phase 2 / National cooperative group (SWOG) 
Stage: Previously treated metastatic colorectal cancer 
Recruitment Status: Recruiting 
What it’s studying: This study is testing whether adding nivolumab (immunotherapy) to encorafenib + cetuximab improves outcomes in BRAF V600E/MSS metastatic CRC. 
Why it matters: Approximately 85–90% of colorectal cancers are MSS. Expanding immunotherapy strategies for this population remains one of the most urgent research priorities in CRC, and to a population that historically does not benefit from single-agent checkpoint inhibitors. 
Patient Tip: If you’ve been told your tumor is MSS and that immunotherapy alone is unlikely to work, ask whether combination immunotherapy trials are available at your treatment center. 
ClinicalTrials.gov: NCT04963283 

5. CIRCULATE-US (NRG-GI008) — ctDNA-Guided Adjuvant Strategy in Stage II/III 

Biomarker Focus: Circulating tumor DNA (ctDNA) 
Phase / Sites: Phase II/III / North America (NRG Oncology) 
Stage: Stage II and III (resected) colon cancer 
Recruitment Status: Recruiting 
What it’s studying: This randomized study evaluates whether post-surgical ctDNA testing can guide escalation or de-escalation of chemotherapy in patients with stage II or III colon cancer. Patients who test ctDNA-positive may receive intensified therapy, while those who test ctDNA-negative may receive less intensive treatment. 
Why it matters: ctDNA is emerging as a precision tool to detect minimal residual disease and personalize adjuvant therapy decisions. 
Patient Tip: If you’ve had surgery for stage II or III colon cancer, ask whether ctDNA testing or enrollment in a ctDNA-guided trial is appropriate for you. 
ClinicalTrials.gov: NCT05174169 

February 2026

1. BRAFTOVI® + Cetuximab + FOLFIRI — New Triplet Regimen for BRAF V600E mCRC

Biomarker Focus: BRAF V600E mutation
Phase / Sites: Phase 2 / Multinational (Pfizer-sponsored)
Stage: Metastatic (mCRC)
Recruitment Status: Active, not recruiting
What it’s studying: This study evaluates the combination of encorafenib + cetuximab + FOLFIRI in patients with previously treated, BRAF V600E-mutated metastatic CRC.
Findings: Results from ASCO GI 2026 show a significant increase in overall response rates (ORR) and progression-free survival compared to historical controls.
Why it matters: Offers a promising targeted therapy option earlier in the treatment journey for patients with BRAF-mutant CRC.
Patient Tip: If your tumor is BRAF V600E-positive and you’ve been previously treated, ask your care team about this combination.
ClinicalTrials.gov: NCT04607421

2. CIRCULATE-North America (NRG-GI008) — ctDNA-Guided Adjuvant Therapy in Stage II/III CRC

Biomarker Focus: Circulating tumor DNA (ctDNA)
Phase / Sites: Phase II/III / North America (NRG Oncology)
Stage: Stage II and III (resected)
Recruitment Status: Recruiting
What it’s studying: This randomized trial evaluates whether ctDNA testing after surgery can guide the need for adjuvant chemotherapy in patients with stage II or III colon cancer. Patients with detectable ctDNA may receive intensified treatment, while ctDNA-negative patients may avoid unnecessary chemotherapy.
Presented: ASCO GI 2026
Why it matters: ctDNA is emerging as a precision tool for assessing minimal residual disease (MRD). This trial could help patients avoid overtreatment—or identify recurrence risk earlier.
Patient Tip: If you’ve had surgery for stage II or III colon cancer, ask if ctDNA testing might inform your follow-up care plan.
ClinicalTrials.gov: ASCO Abstract: NRG-GI008

3. KEYNOTE-975 Subanalysis — Pembrolizumab in dMMR/MSI-H mCRC

Biomarker Focus: dMMR / MSI-H
Phase / Sites: Phase 3 / Global
Stage: Metastatic
Recruitment Status: Ongoing
What it’s studying: Examining the efficacy of pembrolizumab as a first-line treatment for dMMR/MSI-H metastatic CRC.
Findings: Durable responses reported in previously untreated patients, including those with comorbidities and older age groups.
Why it matters: Validates immunotherapy as a frontline option in dMMR CRC—not just for ideal candidates.
Patient Tip: If your tumor is MSI-H or dMMR, ask if you qualify for first-line immunotherapy.
ClinicalTrials.gov: NCT04003636

4. BEACON-Lite Cohort A — Real-World Evaluation of Triplet Therapy in BRAF CRC

Biomarker Focus: BRAF V600E mutation
Phase / Sites: Phase 2 / Expanded access
Stage: Metastatic
Recruitment Status: Closed to new participants
What it’s studying: A cohort evaluating encorafenib + cetuximab + chemotherapy in patients not eligible for the original BEACON trial.
Findings: Preliminary real-world data shows efficacy in older patients and those with comorbidities.
Why it matters: Supports more inclusive criteria for accessing promising triplet regimens.
Patient Tip: If you were previously excluded from BRAF-targeted trials, ask if real-world data may now support this approach.
ClinicalTrials.gov: NCT02928224

January 2026

1. BREAKWATER Trial — Triplet Therapy Sets New Standard for BRAF V600E mCRC

Biomarker Focus: BRAF V600E mutation
Phase / Sites: Phase 3 / Multi-national
Stage: Stage IV (metastatic)
Recruitment Status: Completed (Phase 3)
What it’s studying: Encorafenib + cetuximab + FOLFIRI vs chemotherapy in first-line mCRC
Findings: PFS nearly doubled (12.8 vs 7.1 months); OS improved to 30.3 vs 15.1 months
Why it matters: A new triplet could replace chemo as the standard for BRAF-mutated mCRC
Patient Tip: If you have BRAF V600E-mutant CRC and are starting first-line treatment, ask whether this triplet regimen is being considered.
ClinicalTrials.gov: N/A

2. ATOMIC Trial — Atezolizumab + Chemo in Stage III dMMR CRC

Biomarker Focus: Mismatch repair deficiency (dMMR / MSI-H)
Phase / Sites: Phase 3 / Multi-center
Stage: Stage III (resected)
Recruitment Status: Completed
What it’s studying: mFOLFOX6 with or without atezolizumab after surgery in stage III colon cancer
Findings: 3-year disease-free survival improved to 86.4% vs 76.6%
Why it matters: May change adjuvant therapy for early-stage dMMR CRC
Patient Tip: If your tumor is MSI-H/dMMR and you’re receiving adjuvant chemo, ask whether immunotherapy was considered or studied in your care setting.
ClinicalTrials.gov: NCT02912559

3. IVX037 + Sintilimab in MSS CRC — RNA Virus Therapy for IO-Resistant Tumors

Biomarker Focus: Microsatellite stable (MSS), KRAS mutations
Phase / Sites: Phase 1 / Single site (expansion)
Stage: Stage IV (refractory)
Recruitment Status: Expansion underway (Phase 1a complete)
What it’s studying: A bio-selected, receptor-targeted oncolytic RNA virus (IVX037) injected into tumors, combined with anti-PD-1 sintilimab
Findings: Disease control in patients with MSS and KRAS G12D CRC; early immune activation observed
Why it matters: One of the first intratumoral viral therapies showing benefit in MSS CRC: a population typically unresponsive to immunotherapy
Patient Tip: If your tumor is MSS and you’ve exhausted chemo options, ask your care team about clinical trials exploring novel immunotherapy combinations or virus-based therapies.
ClinicalTrials.gov: N/A

4. DYNAMIC-III Trial — ctDNA-Guided Escalation in Stage III CRC

Biomarker Focus: Circulating tumor DNA (ctDNA)
Phase / Sites: Phase 2 / Australia
Stage: Stage III (resected)
Recruitment Status: Completed
What it’s studying: Use of post-surgical ctDNA to guide chemotherapy intensity
Findings: Escalation based on ctDNA positivity improved outcomes; negative ctDNA patients avoided unnecessary chemo
Why it matters: Further validates ctDNA as a tool for adjuvant therapy decisions
Patient Tip: If you’ve had surgery for stage III CRC, ask if ctDNA testing could help tailor your chemotherapy plan.
ClinicalTrials.gov: NCT03803553

5. Tumor-Agnostic ADC Use in CRC – Real-World Data on KRAS G12C and HER2+ Subtypes
Biomarker Focus: KRAS G12C, HER2, and ADC-responsive profiles
Phase / Sites: Retrospective / Multiple centers
Stage: Stage IV (refractory)
Recruitment Status: Retrospective analysis of real-world patients (not an interventional trial)
What it’s studying: Outcomes among CRC patients treated with tumor-agnostic antibody-drug conjugates (ADCs) in third-line or later settings
Findings: HER2+ and KRAS G12C patients experienced stable disease or prolonged progression-free survival with investigational ADCs
Why it matters: Highlights the transition of novel ADCs from trials to practice and underscores the importance of biomarker matching in refractory mCRC
Patient Tip: If you’ve already tried standard treatments, ask your provider about biomarker testing for targets like HER2 or KRAS G12C, which may open access to novel ADC-based strategies through expanded access or real-world use.
ClinicalTrials.gov: N/A

The post On Our Radar: June 2026 Clinical Trials Roundup appeared first on Fight Colorectal Cancer.

Before you read: know your tumor biology: Many of the treatments below only work for specific tumor types. Your MSI/MMR status, BRAF mutation result, RAS status, and other biomarkers determine which findings apply to you. If you have not had comprehensive biomarker testing, ask your oncologist. 

1. BRAF V600E: A Targeted Combination with Landmark Survival 

Who this is for: Patients with BRAF V600E-mutated metastatic colorectal cancer (~8-10% of all CRC). 

About 8-10% of colorectal cancers carry a BRAF V600E mutation. This mutation is often linked with more aggressive disease, but it also creates a specific target for treatment. 

Ask your doctor: 

• “Does my tumor have a BRAF V600E mutation?” 

• “Am I eligible for the BREAKWATER combination as a first-line treatment?” 

• “Which chemotherapy backbone, such as FOLFOX or FOLFIRI, is the better fit for my health history?” 

2. MSI-H and dMMR: New Evidence on Combining Immunotherapy with Chemotherapy 

Who this is for: Patients with MSI-H (microsatellite instability-high) or dMMR (deficient mismatch repair) metastatic colorectal cancer (about 4-5% of metastatic cases). 

Pembrolizumab monotherapy (KEYNOTE-177, André et al., NEJM 2020) is the current FDA-approved standard for first-line MSI-H/dMMR metastatic CRC. This approach builds on earlier research demonstrating that mismatch repair-deficient tumors are uniquely sensitive to immune checkpoint blockade (Le et al., NEJM 2015). ASCO 2026 presented data examining whether adding chemotherapy and bevacizumab to immunotherapy could further improve outcomes, and whether that benefit is worth the added side effects. 

Ask your doctor: 

• “Is my tumor confirmed MSI-H or dMMR?” 

• “Based on my disease burden, would a more intensive combination approach make sense for me?” 

• “How do you weigh the COMMIT progression benefit against the safety data?” 

3. MSS Colorectal Cancer: Progress for the Majority 

Who this is for: The roughly 85% of colorectal cancer patients whose tumors are microsatellite stable (MSS or pMMR) and typically do not respond to standard immunotherapy. 

Standard immunotherapy alone usually does not work for MSS colorectal cancer. Research in this group focuses on combinations, using targeted therapy, radiation, or chemotherapy to create conditions where immune responses may be more likely. ASCO 2026 had several trials moving this approach forward. 

Ask your doctor: 

• “Has my tumor been fully tested, including BRAF, RAS, KRAS G12C, HER2, and NTRK?” 

• “Are there active trials for MSS colorectal cancer that fit my diagnosis and treatment history?” 

4. ctDNA Testing: A Blood Test That Could Guide Post-Surgery Decisions 

Who this is for: Primarily patients with stage II or III colon cancer who have had surgery and are deciding on next steps. 

After surgery, a key question is whether any cancer cells remain. Circulating tumor DNA (ctDNA) testing looks for fragments of cancer DNA in the bloodstream. A positive result after surgery suggests higher recurrence risk. A negative result suggests lower risk, although it does not guarantee cancer will not return. 

Supporting evidence: The DYNAMIC trial (Tie et al., NEJM 2022) showed ctDNA guidance reduced chemotherapy use from 28% to 15% of stage II patients without compromising recurrence-free survival. The GALAXY study (Nakamura et al., Nature Medicine 2024) found that ctDNA positivity after surgery was associated with dramatically worse disease-free survival (HR 11.99) and overall survival (HR 9.68). 

Ask your doctor: 

• “Am I a candidate for ctDNA testing given my stage and surgical outcome?” 

• “What would a positive or negative ctDNA result mean for my treatment plan?” 

5. GLP-1 Medications: An Emerging Signal in Colorectal Cancer 

Who this is for: Patients who have or may qualify for GLP-1 medications for diabetes, obesity, or cardiovascular risk. This is not a cancer treatment. 

GLP-1 medications were not developed as cancer treatments, but they have generated significant attention across cancer research this year. New findings presented at both ASCO GI and ASCO 2026 raised important questions about whether these medications could influence colorectal cancer risk, progression, or survivorship outcomes. While the evidence is still early, the level of interest from researchers and clinicians makes this an area worth watching.  

Three independent research teams asked whether GLP-1 receptor agonists like semaglutide, liraglutide, or dulaglutide might affect colorectal cancer risk or outcomes. None of these studies proves the medications work as cancer treatment. But taken together, they are interesting enough to study further, but they should not change cancer care on their own.  

Important: These are observational studies showing associations, not proof of benefit. A 2025 meta-analysis (Zhong et al., BMC Gastroenterology 2025) found mixed results depending on the comparison group. Do not start these medications based on cancer concerns alone. 

Ask your doctor: 

• “Do I have a medical reason, such as diabetes, obesity, or cardiovascular risk, to consider a GLP-1 medication?” 

• “If I am already on one, how might it interact with my cancer treatment?” 

Additional Studies Worth Knowing 

These studies may matter for specific patient groups. Some results are mature, while others are early or ongoing, so the right takeaway is to ask whether any of these questions apply to your diagnosis, biomarkers, and treatment history. 

The Bottom Line 

ASCO 2026 was not defined by a single headline. Instead, it highlighted meaningful progress across the colorectal cancer continuum. 

Researchers reported a new standard of care for patients with BRAF V600E-mutated metastatic colorectal cancer, new questions about how best to intensify treatment for selected MSI-H/dMMR tumors, continued efforts to expand immunotherapy strategies for MSS disease, and growing evidence supporting ctDNA-guided treatment decisions after surgery, and emerging research exploring the connections between metabolic health, survivorship, and colorectal cancer outcomes.  

These results do not replace a conversation with your oncologist. But they can help you ask better questions. 

Know your biomarkers. Ask about clinical trials. Talk about quality of life, not just tumor response. And remember: you do not have to navigate this alone. Fight CRC is here to help you understand your options, ask informed questions, and advocate for the care you deserve. 

Sign up for the Clinical Trials Newsletter

Fight CRC Resources 

References 

1a.  Elez et al. NEJM 2025. https://doi.org/10.1056/NEJMoa2501912  

1b.  Kopetz et al. Nature Medicine 2025. https://doi.org/10.1038/s41591-024-03443-3  

1c.  Kopetz et al. ASCO 2026, Abstract LBA3503. NCT04607421.  

2a.  Rocha Lima, Overman et al. ASCO 2026, Abstract 14. NCT02997228.  

2b.  André et al. NEJM 2020. https://doi.org/10.1056/NEJMoa2017699 

2c.  Le et al. NEJM 2015. https://doi.org/10.1056/NEJMoa1500596  

3a.  Morris VK II et al. ASCO 2026, Abstract 3504. SWOG S2107. 

3b.  Bai et al. ASCO 2026, Abstract LBA3515. mRCAT-III. 

4a.  Folprecht, ASCO 2026, Abstract LBA3500. NCT04089631. 

4b.  Tie et al. NEJM 2022. https://doi.org/10.1056/NEJMoa2200075 

4c.  Nakamura et al. Nature Medicine 2024. https://doi.org/10.1038/s41591-024-03254-6 

5a.  Jones et al. ASCO GI 2026, Abstract 18. 

5b.  Arya et al. ASCO GI 2026, Abstract 83. 

5c.  Orland et al. ASCO 2026, Abstract 3143.  

6a. Pietrantonio et al. ASCO 2026, Abstract 3511. CodeBreaK 300. 

6b. EPISODE-III. ASCO 2026, Abstract LBA3508. 

6c. PUMP trial. ASCO 2026, Abstract LBA3506. 

6d. Salazar et al. ASCO 2026, Abstract 3512. CR-SEQUENCE. 

6e. Lenz et al. ASCO 2026, Abstract 3510. CRDF-004. 

6f. Xu et al. ASCO 2026, Abstract LBA3509. 

Medical disclaimer: This blog is for informational purposes only and does not constitute medical advice. Study results may not apply to every patient. Always consult your oncologist before making any treatment decisions. Fight CRC is a patient advocacy organization, not a medical provider. 

The post ASCO 2026: What the Latest Colorectal Cancer Research Means for You  appeared first on Fight Colorectal Cancer.

Front Immunol. 2026 May 19;17:1809281. doi: 10.3389/fimmu.2026.1809281. eCollection 2026.

ABSTRACT

INTRODUCTION: Lynch syndrome (LS) is a hereditary cancer syndrome that increases risk for colorectal and other cancers. We hypothesize that vaccines against tumor-associated antigens CEA, MUC1, and brachyury, simultaneously delivered in an adenovirus serotype-5 vector (Tri-Ad5) combined with the immune-enhancing IL-15 receptor superagonist nogapendekin-alfa-inbakicept (NAI) will reduce the incidence of colorectal neoplasms in LS carriers.

METHODS: In this ongoing phase IIB double-blind placebo-controlled trial, two open-label safety phases (SPs) assessed safety of Tri-Ad5 alone (SP1, n=10) and with added NAI (SP2, n=10). A randomized controlled trial (RCT) follows the SPs. After baseline colonoscopy, vaccine dosing occurs at weeks 0, 4 and 8; Tri-Ad5 alone in SP1 and Tri-Ad5 plus NAI in SP2, with identical boosters at Week 52. The RCT phase participants (n=138) were randomized to receive Tri-Ad5 plus NAI or placebo. All participants complete colonoscopy at Weeks 52 and 104 for assessment of the primary endpoint: cumulative colorectal neoplasm incidence. Secondary endpoints include safety, tolerability, and immunogenicity.

RESULTS: All 20 SP participants (median age 57.5 (range 42-75), 70% female, 15% minority) received all prime and booster series. SP1 participants reported 139 adverse events (AEs) and SP2 participants reported 178. AEs were predominantly grade 1; no treatment-related serious adverse events (SAEs) occurred. The most common treatment-related AEs were reactogenic events including grade 3 rash (without skin necrosis or breakdown) at NAI injection site (100% of SP2 participants). The RCT phase (n=138) recently completed accrual.

DISCUSSION: In LS carriers without active cancer, the combination of Tri-Ad5 + NAI was well-tolerated; the RCT phase is ongoing.

CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/, identifier NCT05419011.

PMID:42238576 | PMC:PMC13226594 | DOI:10.3389/fimmu.2026.1809281

The post Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet) appeared first on Fight Colorectal Cancer.

Clin Gastroenterol Hepatol. 2026 Jun 2:S1542-3565(26)00402-7. doi: 10.1016/j.cgh.2026.05.022. Online ahead of print.

NO ABSTRACT

PMID:42235869 | DOI:10.1016/j.cgh.2026.05.022

The post Birth Cohort Effects on Colorectal Cancer Onset in Lynch Syndrome appeared first on Fight Colorectal Cancer.

JCO Oncol Pract. 2026 May 29:OP2600098. doi: 10.1200/OP-26-00098. Online ahead of print.

ABSTRACT

PURPOSE: In metastatic colorectal cancer (mCRC), testing for mismatch repair deficiency (dMMR) can identify patients who will benefit from immune checkpoint inhibitors (ICIs). Communication regarding molecular testing and ICI is challenging, with studies demonstrating that oncologists have varied knowledge of genomic testing and frequently use technical jargon, and patient understanding is poor. We aimed to characterize discussions of molecular testing and ICIs to identify effective communication strategies.

METHODS: We conducted an observational qualitative study from 2022 to 2023. We recruited US medical oncologists who treat colon cancer. Oncologists participated in recorded telehealth encounters with standardized patients with dMMR mCRC who were referred to discuss treatment. NVivo QSR 14 was used for transcription and code identification via content analysis.

RESULTS: The study included 107 oncologists at 42 institutions across 27 US states who were contacted via email, and 21 (20%) participated. The median age was 41 years, 43% were female, and 33% were non-White. Average encounter duration was 44 minutes 5 seconds. The conversation structure was similar, but descriptions differed. MMR was described using variable terms, most commonly mutation (8/21) and protein loss (8/21). Almost all (20/21) oncologists discussed ICI, and over half (11/20) explained the mechanism. A minority of oncologists (5/21) reported response rates to immunotherapy (30%-70%) and informed of severe side effects. Oncologists uncommonly discussed next-generation sequencing (6/21), while over half (13/21) discussed germline testing.

CONCLUSION: This nationwide sample of oncologists used variable descriptions when discussing MMR and ICI, as evidenced by the use of technical jargon and inconsistent inclusion of key topics, including the likelihood of response and severe adverse events. The use of a structured framework could help oncologists communicate key information to patients more effectively.

PMID:42214055 | DOI:10.1200/OP-26-00098

The post Evaluating Oncologists’ Communication Strategies Regarding Molecular Testing and Immunotherapy appeared first on Fight Colorectal Cancer.

Am Soc Clin Oncol Educ Book. 2026 Jun;46(3):e516572. doi: 10.1200/EDBK-26-516572. Epub 2026 May 28.

ABSTRACT

Squamous cell carcinoma of the anal canal (SCAC) is a rare, human papillomavirus-driven malignancy with a rising global incidence and an increasingly dynamic therapeutic landscape. This review summarizes recent advances and current evidence in the management of SCAC, with a focus on immunotherapy, systemic treatment strategies, and optimization of curative-intent approaches. For locally advanced SCAC, concurrent chemoradiotherapy with fluorouracil and mitomycin C remains the standard of care, on the basis of multiple randomized trials demonstrating improved disease control and organ preservation compared with radiotherapy alone. These studies also show that treatment intensification with alternative chemotherapy, induction therapy, or radiation dose escalation does not improve outcomes. Given the curative intent, maintaining quality of life is a key consideration, and current studies are evaluating radiation dose optimization to reduce treatment-related toxicity, as well as the integration of immunotherapy to improve treatment efficacy. In metastatic SCAC, the combination of carboplatin and paclitaxel is the established first-line chemotherapy backbone. The addition of the PD-1 inhibitor retifanlimab to chemotherapy has demonstrated improved clinical outcomes and is now a preferred first-line approach. In the treatment-refractory setting, anti-PD-1 monotherapy provides modest response rates and remains a standard option for immunotherapy-naïve patients. Together, these findings summarize the current evidence base guiding the management of SCAC.

PMID:42208017 | DOI:10.1200/EDBK-26-516572

The post Updates on Management of Anal Cancer: A New Era Has Begun appeared first on Fight Colorectal Cancer.